{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-070450","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2024-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.592989+00:00","generated_at":"2026-06-01T05:01:27.492738+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Annovis Bio Buntanetap Phase II/III shows statistically significant efficacy in APOE4 Alzheimer's patients","bullets":["In early AD patients (MMSE 21-24), Buntanetap showed -3.3 point ADAS-Cog11 improvement vs baseline and -2.3 vs placebo.","APOE4 carriers on 15mg dose achieved -3.15 point improvement in ADAS-Cog11 scores.","Buntanetap had no ARIA or serious drug-related TEAEs; safety comparable in carriers and non-carriers.","Study included 159 APOE4 carriers (33 homozygotes) and 159 non-carriers.","Company plans 18-month Phase III trial in biomarker-positive early AD patients under FDA guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-070450","json":"https://secwatch.observer/filing/0001104659-24-070450.json","markdown":"https://secwatch.observer/filing/0001104659-24-070450.md","text":"https://secwatch.observer/filing/0001104659-24-070450.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924070450/0001104659-24-070450-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924070450/tm2416963d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:01:27.492738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}